Orion Corporation Completes Share Conversion

On September 4, 2026, Orion Corporation completed the conversion of 102,000 of its A shares into an equivalent number of B shares, as per the company’s Articles of Association. The conversion was recorded in the Trade Register on the same day.

Following the conversion, the company’s share structure now stands at 31,271,179 A shares and 109,863,099 B shares, with the total number of shares remaining unchanged at 141,134,278. The total number of votes has increased to 735,286,679, reflecting the conversion.

Orion Corporation, a globally operating Nordic pharmaceutical company, continues to focus on developing, manufacturing, and marketing human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients. The company’s extensive portfolio includes both proprietary and generic medicines and consumer health products. Its research and development (R&D) priorities include core therapy areas such as oncology and pain management.

In 2025, Orion Corporation reported net sales of €1.89 billion and employed approximately 4,000 professionals worldwide. The company’s commitment to continuous innovation and trusted expertise remains a cornerstone of its operations.